Loading...
Loading...
KYTHERA Biopharmaceuticals
KYTH today announced positive
interim results from a Phase IIIb, multicenter, open-label study
(ATX-101-11-26) of ATX-101 during the “Innovations and Renewals” session
of the 11th Anti-Aging Medicine World Congress (AMWC), April
4-6, Monte Carlo, Monaco. The study, presented by investigator Susan
Weinkle, MD, FAAD, evaluated the safety and efficacy of ATX-101, a
potential first-in-class, non-surgical, injectable drug in Phase III
trials for the reduction of unwanted submental fat (SMF), commonly known
as “double chin.” The results found that ATX-101 is well tolerated and
may be effective in reducing SMF by both clinician- and patient-reported
outcome measures. AMWC is the world's largest event for global aging
management, and attracts aesthetic dermatologists, surgeons and
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in